Three key studies of COVID-19 vaccines to launch in summer

Jun. 10, 2020 11:19 AM ETModerna, Inc. (MRNA), AZN, JNJ, PFE, BNTX, SNY, MRKJNJ, PFE, MRK, SNY, AZN, MRNA, BNTXBy: Douglas W. House, SA News Editor27 Comments
  • The WSJ reports that the federal government (National Institutes of Health) plans to fund and conduct pivotal studies of three COVID-19 vaccine candidates starting this summer.
  • The large-scale trials will test Moderna's (MRNA +3.8%) mRNA-1273 starting next month, Oxford University and AstraZeneca's (AZN +2.2%) AZD1222 in August and Johnson & Johnson's (JNJ +1.4%) Ad26.COV2-S in September. Each is projected to enroll ~30K people.
  • Pfizer (PFE -0.4%), which is not participating in the NIH testing program, together with collaboration partner BioNTech SE (BNTX -0.8%), plans to launch a Phase 3 study on its candidate, BNT162, as early as next month (four variants of the vaccine are currently being tested).
  • The feds may include additional large-scale studies of other vaccine candidates, such as those being developed by Sanofi (SNY +0.9%) and Merck (MRK -1.1%) according Dr. Larry Corey, a member of the committee advising NIH on the design of the trials.

Recommended For You

Comments (27)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.